Limited Impact of 2 g/day Omega-3 Fatty Acid Ethyl Esters (Omacor®) on Plasma Lipids and Inflammatory Markers in Patients Awaiting Carotid Endarterectomy

Autor: Simon P. K. Payne, A.L. Cawood, Jennifer A. Williams, Robert F. Grimble, Philip C. Calder, Frances L. Napper, Hayati Mohd Yusof, Ren Ding, Clifford P. Shearman
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Carotid Artery Diseases
Male
medicine.medical_treatment
Pharmaceutical Science
Blood Pressure
Carotid endarterectomy
fish oil
chemistry.chemical_compound
cardiovascular disease
Drug Discovery
cytokine
Pharmacology
Toxicology and Pharmaceutics (miscellaneous)
lcsh:QH301-705.5
chemistry.chemical_classification
Endarterectomy
Carotid
Esters
Lipids
Eicosapentaenoic acid
adhesion molecule
Lipoproteins
LDL
Drug Combinations
Cholesterol
Eicosapentaenoic Acid
Docosahexaenoic acid
Matrix Metalloproteinase 2
Female
omega-3
E-Selectin
medicine.medical_specialty
Docosahexaenoic Acids
Vascular Cell Adhesion Molecule-1
Article
Internal medicine
Fatty Acids
Omega-3
medicine
Humans
Omega 3 fatty acid
Triglycerides
Aged
Inflammation
Triglyceride
Fatty acid
Surgery
Blood pressure
Endocrinology
chemistry
lcsh:Biology (General)
Biomarkers
Zdroj: Marine Drugs, Vol 11, Iss 9, Pp 3569-3581 (2013)
Marine Drugs; Volume 11; Issue 9; Pages: 3569-3581
Marine Drugs
ISSN: 1660-3397
Popis: The objective of this study was to determine the effects of prescription omega-3 (n-3) fatty acid ethyl esters (Omacor®) on blood pressure, plasma lipids, and inflammatory marker concentrations in patients awaiting carotid endarterectomy. Patients awaiting carotid endarterectomy (n = 121) were randomised to Omacor® or olive oil as placebo (2 g/day) until surgery (median 21 days). Blood pressure, plasma lipids, and plasma inflammatory markers were determined. There were significant decreases in systolic and diastolic blood pressure and in plasma triglyceride, total cholesterol, low density lipoprotein-cholesterol, soluble vascular cellular adhesion molecule 1, and matrix metalloproteinase 2 concentrations, in both groups. The extent of triglyceride lowering was greater with Omacor® (25%) compared with placebo (9%). Soluble E-selectin concentration was significantly decreased in the Omacor® group but increased in the placebo group. At the end of the supplementation period there were no differences in blood pressure or in plasma lipid and inflammatory marker concentrations between the two groups. It is concluded that Omacor® given at 2 g/day for an average of 21 days to patients with advanced carotid atherosclerosis lowers triglycerides and soluble E-selectin concentrations, but has limited broad impact on the plasma lipid profile or on inflammatory markers. This may be because the duration of intervention was too short or the dose of n-3 fatty acids was too low.
Databáze: OpenAIRE
Externí odkaz: